Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)

Catherine R. Hanna*, Sean M. O’Cathail, Janet S. Graham, Mark Saunders, Leslie Samuel, Mark Harrison, Lynsey Devlin, Joanne Edwards, Daniel R. Gaya, Caroline A. Kelly, Liz Anne Lewsley, Noori Maka, Paula Morrison, Louise Dinnett, Susan Dillon, Jacqueline Gourlay, Jonathan J. Platt, Fiona Thomson, Richard A. Adams, Campbell S.D. Roxburgh

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

5 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)'. Together they form a unique fingerprint.

Medicine & Life Sciences